Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Xencor Inc (XNCR)

Xencor Inc (XNCR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,958,769
  • Shares Outstanding, K 56,620
  • Annual Sales, $ 40,600 K
  • Annual Income, $ -70,410 K
  • 60-Month Beta 1.37
  • Price/Sales 47.41
  • Price/Cash Flow N/A
  • Price/Book 3.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.58
  • Number of Estimates 4
  • High Estimate -0.53
  • Low Estimate -0.63
  • Prior Year 0.05
  • Growth Rate Est. (year over year) -1,260.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.40 +1.80%
on 10/02/19
37.44 -9.19%
on 09/20/19
-1.38 (-3.90%)
since 09/13/19
3-Month
33.40 +1.80%
on 10/02/19
46.33 -26.61%
on 08/06/19
-10.34 (-23.32%)
since 07/12/19
52-Week
27.75 +22.52%
on 03/14/19
46.33 -26.61%
on 08/06/19
-1.04 (-2.97%)
since 10/12/18

Most Recent Stories

More News
Xencor to Present at the 2019 Cantor Global Healthcare Conference

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today...

XNCR : 34.00 (-1.72%)
Xencor Appoints Celia Eckert as Vice President, General Counsel and Corporate Secretary

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today...

XNCR : 34.00 (-1.72%)
Xencor Inc has the Best Relative Performance in the Biotechnology Industry (XNCR , ADMS , AIMT , KPTI , MNTA )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

ADMS : 3.90 (+3.72%)
AIMT : 24.21 (-1.38%)
XNCR : 34.00 (-1.72%)
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 33.33% and 156.99%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

XNCR : 34.00 (-1.72%)
Xencor: 2Q Earnings Snapshot

MONROVIA, Calif. (AP) _ Xencor Inc. (XNCR) on Tuesday reported a loss of $16 million in its second quarter.

XNCR : 34.00 (-1.72%)
Xencor Reports Second Quarter 2019 Financial Results

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today...

XNCR : 34.00 (-1.72%)
Xencor Inc Shares Up 30.6% Since SmarTrend's Buy Recommendation (XNCR)

SmarTrend identified an Uptrend for Xencor Inc (NASDAQ:XNCR) on June 18th, 2019 at $33.71. In approximately 1 month, Xencor Inc has returned 30.60% as of today's recent price of $44.02.

XNCR : 34.00 (-1.72%)
Xencor to Present at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today...

XNCR : 34.00 (-1.72%)
Xencor to Host Second Quarter 2019 Financial Results Webcast and Conference Call on August 6, 2019

Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer, autoimmune diseases, asthma and allergic diseases, today...

XNCR : 34.00 (-1.72%)
31.6% Return Seen to Date on SmarTrend Xencor Inc Call (XNCR)

SmarTrend identified an Uptrend for Xencor Inc (NASDAQ:XNCR) on June 18th, 2019 at $33.71. In approximately 1 month, Xencor Inc has returned 31.58% as of today's recent price of $44.35.

XNCR : 34.00 (-1.72%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak.

See More Share

Trade XNCR with:

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

2nd Resistance Point 35.19
1st Resistance Point 34.59
Last Price 34.00
1st Support Level 33.66
2nd Support Level 33.33

See More

52-Week High 46.33
Fibonacci 61.8% 39.23
Fibonacci 50% 37.04
Fibonacci 38.2% 34.85
Last Price 34.00
52-Week Low 27.75

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar